Role of TSH measurements in predicting the outcome of treatment for Graves' disease following drug therapy.
Thyroid-stimulating hormone (TSH) levels obtained one month after the cessation of anti-thyroid drug treatment were assessed retrospectively for possible use in predicting outcome in 50 patients with a clinical diagnosis of Graves' disease. Thirty-four patients remained in remission at the end of the follow-up period and 16 patients relapsed. Although a TSH level of < 1.2 mU/1 did not discriminate between the two groups, none of the 24 patients who had TSH levels of > 1.2 mU/1 relapsed during the follow-up period, making early discharge from the thyroid clinic possible for these patients.
Wood
W E
WE
Department of Chemical Pathology, Greenwich District Hospital, Vanbrugh Hill, London, UK.
D000328:Adult; D002231:Carbimazole / Q000627:therapeutic use; D005260:Female; D006111:Graves Disease / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D011441:Propylthiouracil / Q000627:therapeutic use; D012008:Recurrence; D012189:Retrospective Studies; D013972:Thyrotropin / Q000097:blood*; D013997:Time Factors; D016896:Treatment Outcome
D011441:Propylthiouracil; D002231:Carbimazole; D013972:Thyrotropin